Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep;107(9):1193-7.
doi: 10.1111/cas.12986. Epub 2016 Aug 25.

Lymphocyte-activation gene-3, an important immune checkpoint in cancer

Yayi He  1   2 , Christopher J Rivard  2 , Leslie Rozeboom  2 , Hui Yu  2 , Kim Ellison  2 , Ashley Kowalewski  2 , Caicun Zhou  3 , Fred R Hirsch  4
Affiliations
Review

Lymphocyte-activation gene-3, an important immune checkpoint in cancer

Yayi He et al. Cancer Sci. 2016 Sep.

Abstract

Immunotherapy has recently become widely used in lung cancer. Many oncologists are focused on cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed cell death ligand-1 (PD-L1) and programmed cell death-1 (PD-1). Immunotherapy targeting the PD-1/PD-L1 checkpoints has shown promising efficacy in non-small cell lung cancer (NSCLC), but questions remain to be answered. Among them is whether the simultaneous inhibition of other checkpoints could improve outcomes. Lymphocyte-activation gene-3 (LAG-3) is another vital checkpoint that may have a synergistic interaction with PD-1/PD-L1. Here we review the LAG-3 function in cancer, clinical trials with agents targeting LAG-3 and the correlation of LAG-3 with other checkpoints.

Keywords: Cancer checkpoints; clinical trial; immunotherapy; lymphocyte-activation gene-3; soluble LAG-3.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Some checkpoint pathways in cancer. The lymphocyte‐activation gene‐3 (LAG‐3) protein binds a nonholomorphic region of MHC class II.
Figure 2
Figure 2
Lymphocyte‐activation gene‐3 (LAG‐3)/MHC class II and PD‐1/PD‐L1 pathways. LAG‐3 has synergistic action with PD‐1/PD‐L1.
See this image and copyright information in PMC

References

    1. Couzin‐Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013; 342: 1432–3. - PubMed
    1. Dong H, Zhu G, Tamada K, Chen L. B7‐H1, a third member of the B7 family, co‐stimulates T‐cell proliferation and interleukin‐10 secretion. Nat Med 1999; 5: 1365–9. - PubMed
    1. Dong H, Strome SE, Salomao DR et al Tumor‐associated B7‐H1 promotes T‐cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793–800. - PubMed
    1. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007; 8: 239–45. - PubMed
    1. Brahmer JR, Drake CG, Wollner I et al Phase I study of single‐agent anti‐programmed death‐1 (MDX‐1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167–75. - PMC - PubMed

MeSH terms